Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK

References

• Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis 2002;13(Suppl 1):1–6
   PubMedGoogle Scholar
• Nenci GG. Unifying concept of arterial vascular disease. Eur Heart J 1999;1(Suppl A):A27–A30
   Google Scholar
• Dormandy J, Heeck L, Vig S. Lower-extremity arteriosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease. Semin Vasc Surg 1999;12:118–22
   Google Scholar
• Lichtman JH, Krumholz HM, Wang Y, et al. Risk and predictors of stroke after myocardial infarction among the elderly. Results from the Cooperative Cardiovascular Project. Circulation 2002;105:1082–7
   Google Scholar
• Petersen S, Rayner M. Coronary heart disease statistics – 2002 edition [online]. Available from http://www.dphpc.ox.ac.uk/ bhfhprg/stats/2000/index html 2002
   Google Scholar
• Department of Health. National service framework for older people [online]. Available from http://www.doh.gov.uk/nsf/ olderpeople htm 2001
   Google Scholar
• Bamford J, Sandercock P, Dennis M, et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981–86. 1. Methodology, demography and incident cases of first-ever stroke. J Neurol Neurosurg Psychiatry 1988;51: 1373–80
   Google Scholar
• Fowkes FGR. Peripheral vascular disease, third series [online]. 2003. Available from http://hcna.radcliffe-oxford.com 2003
   Google Scholar
• Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997;2:221–6
   PubMedGoogle Scholar
• Stoffers HEJH, Rinkens PELM, Kester ADM, et al. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. Int J Epidemiol 1996;25:282–90
   PubMed Web of Science ®Google Scholar
• Liu JLY, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002;88:597–603
   PubMed Web of Science ®Google Scholar
• Bosanquet N, Franks P, for The Stroke Association. Stroke care: reducing the burden of disease. London: The Stroke Association; 1998
   Google Scholar
• Johnson BF, Evans L, Drury R, et al. Surgery for limb threatening ischaemia: a reappraisal of the costs and benefits. Eur J Vasc Endovasc Surg 1995;9:181–8
   PubMed Web of Science ®Google Scholar
• de Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601–10
   Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71–86
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed) 1988;296:320–31
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308:81–106
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–39
   PubMed Web of Science ®Google Scholar
• Annemans L, Lamotte M, Levy E, Lenne X. Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. J Med Econ 2003; 6:43–56
   Google Scholar
• Ho WK, Hankey GJ, Eikelboom JW. Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. Expert Opin Pharmacother 2004;5:493–503
   Google Scholar
• Gaspoz J-M, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. New Engl J Med 2002;346:1800–6
   Google Scholar
• Haldemann R, Szucs TD, Lüscher T. Rentabilité du clopidogrel dans la prévention secondaire cardiovasculaire: une analyse coût-efficacité sur la base de l’étude CAPRIE. Med Hyg 2001;59:1749–54 [French]
   Google Scholar
• Overell JR, Walker A, Weir CJ, Lees KR. The cost effectiveness of clopidogrel and the combination of aspirin and dipyridamole in stroke prevention. Cerebrovasc Dis 1999;9(Suppl 1):66
   Google Scholar
• Sarasin FP, Gaspoz J-M, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med 2000;160:2773–8
   Google Scholar
• Shah H, Gondek K. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. Clin Ther 2000;22:362–70
   PubMed Web of Science ®Google Scholar
• van Hout BA, Tangelder MJD, Bervoets P, Gabriel S. Cost-effectiveness analysis of antithrombotic treatment with clopidogrel in patients with myocardial infarction, stroke and peripheral arterial disease in the Netherlands. Poster presented at ISPOR, Barcelona, Spain, November 9–11 2003; PCV27
   Google Scholar
• Haldemann R, Luscher TF, Szucs TD. Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study. Schweiz Rundsch Med Prax 2001;90:539–45 [German]
   Google Scholar
• Gray D, Hampton JR. Twenty years’ experience of myocardial infarction: the value of a heart attack register. Br J Clin Pharmacol 1993;47:292–5
   Web of Science ®Google Scholar
• Wolfe CDA, Rudd AG, Howard R, et al. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J Neurol Neurosurg Psychiatry 2002;72:211–6
   PubMed Web of Science ®Google Scholar
• Smith FB, Rumley A, Lee AJ, et al. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998;100:758–63
   PubMed Web of Science ®Google Scholar
• Palmer S, Sculpher M, Philips Z, et al. A cost-effectiveness model comparing alternative management strategies for the use of glycoprotein IIb/IIIa antagonists in non-ST-elevation acute coronary syndrome. NICE appraisal report 2002 [online]. Available from http://www.nice.org.uk [accessed Aug 2003]
   Google Scholar
• Chambers M, Hutton J, Gladman J. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin–dipyridamole. Pharmaco economics 1999;16:577–93
   Google Scholar
• Joint Formulary Committee. British National Formulary, 44th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2002
   Google Scholar
• National Institute for Clinical Excellence. Guidance for manufacturers and sponsors [online]. Available from www.nice.org.uk 2001 [accessed August 2003]
   Google Scholar
• Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 2003;21:191–200
   PubMed Web of Science ®Google Scholar
• Derdeyn CP, Powers WJ. Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease. Stroke 1996;27:1944–50
   PubMed Web of Science ®Google Scholar
• Salkeld G, Phongsavan P, Oldenburg B, et al. The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy 1997;41:105–19
   PubMed Web of Science ®Google Scholar
• Zeckhauser R, Shepard D. Where now for saving lives? Law Contemp Probs 1976;40:5–45
   Google Scholar
• Haigh R, Castleden M, Woods K, et al. Management of myocardial infarction in the elderly: admission and outcome on a coronary care unit. Health Trends 1991;23:154–7
   PubMedGoogle Scholar
• Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996;94:957–65
   PubMed Web of Science ®Google Scholar
• Lee TT, Solomon NA, Heidenreich PA, et al. Cost-effectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med 1997;126:337–46
   PubMed Web of Science ®Google Scholar
• Danese MD, Powe NR, Sawin CT, Ladenson PW. Screening for mild thyroid failure at the periodic health examination. J Am Med Assoc 1996;276:285–92
   PubMed Web of Science ®Google Scholar
• Boland A, Dundar Y, Bagust A, et al. Early thrombolysis for the treatment of acute myocardial infarction. NICE appraisal report 2002 [online]. Available from http://www.nice.org.uk [accessed March 2004]
   Google Scholar
• Wessex Institute for Health Research and Development. Implantable cardioverter defibrillators: arrhythmias. NICE appraisal report 2000 [online]. Available from http://www.nice. org.uk [accessed March 2004]
   Google Scholar
• Ringleb PA, Bhatt DL, Hirsch AT, et al. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004;35:528–32
   PubMed Web of Science ®Google Scholar